Literature DB >> 30898394

The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.

Laura L Stafman1, Mary G Waldrop1, Adele P Williams1, Jamie M Aye2, Jerry E Stewart1, Elizabeth Mroczek-Musulman3, Karina J Yoon4, Kimberly Whelan2, Elizabeth A Beierle5.   

Abstract

PURPOSE: Hepatoblastoma is the most common primary liver cancer of childhood and has few prognostic indicators. We have previously shown that Proviral Integration site for Moloney murine leukemia virus (PIM3) kinase decreased hepatoblastoma tumorigenicity. We sought to determine the effect of PIM3 overexpression on hepatoblastoma cells and whether expression of PIM3 correlated with patient/tumor characteristics or survival.
METHODS: The hepatoblastoma cell line, HuH6, and patient-derived xenograft, COA67, were utilized. Viability, proliferation, migration, sphere formation, and tumor growth in mice were assessed in PIM3-overexpressing cells. Immunohistochemistry was performed for PIM3 on patient samples. Correlation between stain score and clinical/pathologic characteristics was assessed.
RESULTS: PIM3 overexpression rescued the anti-proliferative effect observed with PIM3 knockdown. Sphere formation was increased in PIM3 overexpressing cells. Cells with PIM3 overexpression yielded larger tumors than those with empty vector. Seventy-four percent of samples expressed PIM3. There was no statistical difference in patient characteristics between subjects with strong versus weak PIM3 staining, but patients with strong PIM3 staining had decreased survival.
CONCLUSIONS: PIM3 expression plays a role in hepatoblastoma tumorigenesis. PIM3 was present in the majority of hepatoblastomas and higher PIM3 expression correlated with decreased survival. PIM3 warrants investigation as a therapeutic target and prognostic marker for hepatoblastoma.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Hepatoblastoma; PIM kinases; PIM3; Survival

Mesh:

Substances:

Year:  2019        PMID: 30898394      PMCID: PMC6545248          DOI: 10.1016/j.jpedsurg.2019.02.029

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  28 in total

Review 1.  Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis.

Authors:  Z Wang; N Bhattacharya; M Weaver; K Petersen; M Meyer; L Gapter; N S Magnuson
Journal:  J Vet Sci       Date:  2001-12       Impact factor: 1.672

2.  Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site.

Authors:  Teija L T Aho; Jouko Sandholm; Katriina J Peltola; Harri P Mankonen; Michael Lilly; Päivi J Koskinen
Journal:  FEBS Lett       Date:  2004-07-30       Impact factor: 4.124

3.  Small cell undifferentiated histology in hepatoblastoma may be unfavorable.

Authors:  J E Haas; J H Feusner; M J Finegold
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

4.  Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase.

Authors:  Zeping Wang; Nandini Bhattacharya; Philip F Mixter; Wenyi Wei; John Sedivy; Nancy S Magnuson
Journal:  Biochim Biophys Acta       Date:  2002-12-16

5.  Epidemiology of primary hepatic malignancies in U.S. children.

Authors:  Anil Darbari; Keith M Sabin; Craig N Shapiro; Kathleen B Schwarz
Journal:  Hepatology       Date:  2003-09       Impact factor: 17.425

6.  Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience.

Authors:  Maretta De Ioris; Laurence Brugieres; Arthur Zimmermann; Jean Keeling; Penelope Brock; Rudolf Maibach; Jon Pritchard; Liz Shafford; Joszef Zsiros; Piotr Czaudzerna; Giorgio Perilongo
Journal:  Eur J Cancer       Date:  2007-12-31       Impact factor: 9.162

7.  E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.

Authors:  T Möröy; S Verbeek; A Ma; P Achacoso; A Berns; F Alt
Journal:  Oncogene       Date:  1991-11       Impact factor: 9.867

8.  Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.

Authors:  Daisuke Morishita; Ryohei Katayama; Kazuhisa Sekimizu; Takashi Tsuruo; Naoya Fujita
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

9.  Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines.

Authors:  Chifumi Fujii; Yasunari Nakamoto; Peirong Lu; Koichi Tsuneyama; Boryana K Popivanova; Shuichi Kaneko; Naofumi Mukaida
Journal:  Int J Cancer       Date:  2005-03-20       Impact factor: 7.396

10.  KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA.

Authors:  Fang Cheng; Magdalena Weidner-Glunde; Markku Varjosalo; Eeva-Marja Rainio; Anne Lehtonen; Thomas F Schulz; Päivi J Koskinen; Jussi Taipale; Päivi M Ojala
Journal:  PLoS Pathog       Date:  2009-03-06       Impact factor: 6.823

View more
  7 in total

1.  PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.

Authors:  Nikita Wadhwani; Hooper R Markert; Raoud Marayati; Laura V Bownes; Colin H Quinn; Jamie M Aye; Jerry E Stewart; Karina J Yoon; Elizabeth A Beierle
Journal:  J Pediatr Surg       Date:  2021-02-24       Impact factor: 2.549

2.  Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts.

Authors:  Laura L Stafman; Adele P Williams; Raoud Marayati; Jamie M Aye; Hooper R Markert; Evan F Garner; Colin H Quinn; Shoeb B Lallani; Jerry E Stewart; Karina J Yoon; Kimberly Whelan; Elizabeth A Beierle
Journal:  Sci Rep       Date:  2019-09-13       Impact factor: 4.379

3.  Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma.

Authors:  Alexander Bondoc; Kathryn Glaser; Kang Jin; Charissa Lake; Stefano Cairo; James Geller; Gregory Tiao; Bruce Aronow
Journal:  Commun Biol       Date:  2021-09-08

4.  CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.

Authors:  Raoud Marayati; Laura L Stafman; Adele P Williams; Laura V Bownes; Colin H Quinn; Hooper R Markert; Juliet L Easlick; Jerry E Stewart; David K Crossman; Elizabeth Mroczek-Musulman; Elizabeth A Beierle
Journal:  Cancer Gene Ther       Date:  2021-04-16       Impact factor: 5.854

5.  Targeting Host PIM Protein Kinases Reduces Mayaro Virus Replication.

Authors:  Madelaine Sugasti-Salazar; Dalkiria Campos; Patricia Valdés-Torres; Paola Elaine Galán-Jurado; José González-Santamaría
Journal:  Viruses       Date:  2022-02-18       Impact factor: 5.048

Review 6.  The Role of PIM Kinases in Pediatric Solid Tumors.

Authors:  Janet Rae Julson; Raoud Marayati; Elizabeth Ann Beierle; Laura Lee Stafman
Journal:  Cancers (Basel)       Date:  2022-07-22       Impact factor: 6.575

7.  PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.

Authors:  Raoud Marayati; Laura L Stafman; Adele P Williams; Laura V Bownes; Colin H Quinn; Jamie M Aye; Jerry E Stewart; Karina J Yoon; Joshua C Anderson; Christopher D Willey; Elizabeth A Beierle
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.